Zobrazeno 1 - 10
of 5 512
pro vyhledávání: ''
Autor:
Alicia Probst, Emilie De Carli, Isabelle Aerts, Pascal Chastagner, Natacha Entz-Werle, Caroline Solas, Anne-Isabelle Bertozzi-Salamon, Nicolas André, Anne Pagnier, Emmanuelle Tresch-Bruneel, Pierre Leblond, Jacques Grill, Didier Frappaz, Mourad Hamimed, Florence Gattacceca
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15131⟩
AIM There is a crucial need for pharmacokinetic (PK) data of oral vinorelbine (VNR) in pediatric population. The aim of this work was to assess the PK profile of orally administered VNR in children with recurrent/progressive primary low-grade glioma
Autor:
Ilkka Ilonen, Ville Kytö, Sanna Laaksonen, Jari Räsänen, Marjukka Myllärniemi, Juuso Paajanen, Paulus Torkki
Publikováno v:
Thoracic Cancer, Vol 12, Iss 19, Pp 2594-2600 (2021)
Thoracic Cancer
Thoracic Cancer
Background Substantial variation in health care costs for malignant pleural mesothelioma (MPM) has previously been identified. Materials and Methods We analyzed the changes in health care costs in MPM in Finland during 2002–2012. Finland has low‐
Autor:
Kuittinen Taru, Mäntymaa Pentti, Siitonen Timo, Penttilä Karri, Pelkonen Jukka, Putkonen Mervi, Valtola Jaakko, Varmavuo Ville, Turunen Antti, Silvennoinen Raija, Sankelo Marja, Pyörälä Marja, Partanen Anu, Jantunen Esa, Sikiö Anu
Publikováno v:
Transfusion. 61:3202-3212
Background Scarce data exist on the impact of granulocyte-colony stimulating factor (G-CSF) type on the mobilizing capacity of CD34+ cells, graft cellular composition, and outcome in myeloma (MM) patients. Patients and methods In this prospective mul
Autor:
Daneng Li, Nicolas Sommer, Wendy Verret, Riad Salem, Riccardo Lencioni, Sairy Hernandez, Beiying Ding
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5437-5447 (2021)
Cancer Medicine
Cancer Medicine
Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Explo
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5246-5255 (2021)
Cancer Medicine
Cancer Medicine
Background Recent studies highlight the regulatory role of arachidonate lipoxygenase5 (Alox5) and its metabolite 5‐hydroxyeicosatetraenoic acid (5‐HETE) in cancer tumorigenesis and progression. In this study, we analyzed the expression, biologica
Autor:
Michal Sýkora, Lukas Stejskal, Alexandra Jungova, Vladimir Maisnar, Petr Kessler, Viera Sandecká, Jana Ullrychova, Adriana Heindorfer, Luděk Pour, Tomas Pika, Jan Straub, Martin Stork, Jiří Minařík, Lucie Brožová, Roman Hájek, Ivan Spicka, Tomas Jelinek, Petr Pavlicek, David Starostka, Sabina Ševčíková, Jakub Radocha, Marek Wrobel
Publikováno v:
European Journal of Haematology. 107:466-474
Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and methods We analyzed data from the Registry of Monoclonal Gammopath
Autor:
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, Amélie Biron, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin‐Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean‐Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Maria Nachury, Aurelien Amiot, Franck Brazier, Clara Yzet, Xavier Hebuterne, Guillaume Cadiot, Hedia Brixi, Pauline Rivière, Florian Poullenot, Xavier Treton, Carmen Stefanescu, Camille Zallot, Laurent Beaugerie, Philippe Seksik, Harry Sokol, Julien Kirchgesner, Gilles Boschetti, Bernard Flourié, Claire Gay, Pauline Danion, Chloe Venturin, Matthieu Allez, Clotilde Baudry, Benjamin Pariente, Pauline Wils, Charlotte Gagnière, Jenny Tannoury
Publikováno v:
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2021, 54 (7), pp.944-951. ⟨10.1111/apt.16544⟩
Alimentary Pharmacology and Therapeuthics, 2021, 54 (7), pp.944-951. ⟨10.1111/apt.16544⟩
International audience; Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available. Aims To assess the real-world effectiveness and safety
Autor:
Keita Kudo, Tomomi Masuda, Toshiyuki Harada, Kazuhiro Usui, Eiki Kikuchi, Yukihiro Hasegawa, Akira Inoue, Satoshi Oizimi, Atsushi Nakamura, Makoto Maemondo, Tatsuro Fukuhara, Yuka Fujita, Ryoichi Honda, Hiroshi Yokouchi, Hiroshi Watanabe, Naomi Watanabe, Hisashi Tanaka, Ryota Saito, Naoto Morikawa, Yasutaka Kawai
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Thoracic Cancer
Thoracic Cancer
Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label randomized pha
Autor:
Nichole M. Doyle, Stephanie R. McGuire
Publikováno v:
World Journal of Otorhinolaryngology-Head and Neck Surgery
World Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 7, Iss 3, Pp 179-185 (2021)
World Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 7, Iss 3, Pp 179-185 (2021)
Tonsillectomy with and without adenoidectomy is a frequently performed surgical procedure in children. Although a common procedure, it is not without significant risk. It is critical for anesthesiologists to consider preoperative, intraoperative, and
Autor:
Nirav Patil, Ankit Mangla, Asrar Alahmadi, Nelroy Jones, Richard T. Lee, David L. Bajor, Jill S. Barnholtz-Sloan, Eva Selfridge, Amr Mohamed, Gino Cioffi, Aman Opneja, Tin-Yun Tang, Joel N. Saltzman
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4397-4404 (2021)
Cancer Medicine
Cancer Medicine
Background This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. Methods Adult patients diagnos